Catalent, Inc. (CTLT)
- Previous Close
56.03 - Open
56.04 - Bid 55.79 x 1200
- Ask 56.19 x 1200
- Day's Range
55.79 - 56.07 - 52 Week Range
31.45 - 60.20 - Volume
1,922,754 - Avg. Volume
2,755,935 - Market Cap (intraday)
10.125B - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-7.18 - Earnings Date May 17, 2024 - May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.70
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
www.catalent.com18,000
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: CTLT
Performance Overview: CTLT
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTLT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTLT
Valuation Measures
Market Cap
10.14B
Enterprise Value
14.92B
Trailing P/E
--
Forward P/E
37.74
PEG Ratio (5yr expected)
2.05
Price/Sales (ttm)
2.48
Price/Book (mrq)
2.75
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
-19.79
Financial Highlights
Profitability and Income Statement
Profit Margin
-31.77%
Return on Assets (ttm)
-0.74%
Return on Equity (ttm)
-30.28%
Revenue (ttm)
4.1B
Net Income Avi to Common (ttm)
-1.3B
Diluted EPS (ttm)
-7.18
Balance Sheet and Cash Flow
Total Cash (mrq)
229M
Total Debt/Equity (mrq)
135.99%
Levered Free Cash Flow (ttm)
49.88M
Research Analysis: CTLT
Company Insights: CTLT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CTLT
The Argus Mid-Cap Model Portfolio
Small- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
Analyst Report: Catalent, Inc.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
RatingPrice TargetAnalyst Report: Catalent, Inc.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
RatingPrice TargetAnalyst Report: Catalent, Inc.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
RatingPrice Target